Used primarily in oncology, this compound functions as a multi-targeted tyrosine kinase inhibitor. It interferes with the signaling pathways that drive uncontrolled cell growth, making it effective in treating certain cancers. It is commonly prescribed for advanced renal cell carcinoma and gastrointestinal stromal tumors that cannot be surgically removed or have spread. The agent helps slow tumor progression by inhibiting angiogenesis and tumor cell proliferation through blockade of receptors like VEGFR, PDGFR, and KIT. Its oral formulation allows for outpatient treatment, improving patient convenience. Due to its mechanism, it is also investigated for use in other solid tumors and resistant cancer types.